Pilot Assessment of an Auto Blood Pressure Monitor

Sponsor
William Marsh Rice University (Other)
Overall Status
Completed
CT.gov ID
NCT02258256
Collaborator
University of Malawi (Other)
11
1
1
31
0.4

Study Details

Study Description

Brief Summary

The purpose of the study is to help make a lower cost automatic blood pressure monitor device for diagnosis and monitoring of pre-eclampsia in pregnant women, where automatic blood pressure monitoring is limited or not available. The study will compare this low cost device to a commercially available system used for pre-eclamptic women in many United States hospitals that the investigators will be bringing to Malawi as a part of this study.

The team hopes to show that this lower cost blood pressure machine works well and can help women with pre-eclampsia. The study also aims to see if this machine is easy for the nurse to use.

20 women who are either at-risk or diagnosed with pre-eclampsia will be enrolled at Queen Elizabeth Central Hospital. First, a nurse will fit the test device cuff on one arm of the subject and the commercially available cuff on the opposite arm. A trained research assistant and the nurse will record the blood pressure measurements and document any alarm indications made by each device. Blood pressure measurements will continue until monitoring is no longer clinically prescribed.

The results of this study will help researchers understand the performance and usability of this device in Malawi and help decide if any design changes are needed.

Condition or Disease Intervention/Treatment Phase
  • Device: Sphygmo
N/A

Detailed Description

The research team at Rice University has developed Sphygmo, an automatic blood pressure monitor to be used for the monitoring and diagnosis of pre-eclampsia in pregnant women, particularly in low-resource settings where current blood pressure monitoring is limited. This study aims to evaluate the capabilities of the device in the setting for which it was designed - a low-resource hospital.

This study will compare the Sphygmo device to a commercially available automatic blood pressure monitor that is used in pre-eclamptic women. The main objective of this study is to determine whether the Sphygmo device correctly identifies instances where blood pressure measurement meets the diagnostic criteria for mild or severe pre-eclampsia during monitoring of at-risk mothers. Additionally, this study aims to understand the frequency and type of any complications associated with use of the Sphygmo in a resource-limited clinical setting.

The study will include 20 eligible and consenting women at QECH who are clinically identified as at-risk for pre-eclampsia or have already been diagnosed with pre-eclampsia by their doctors. All participants will undergo the same protocol (monitoring with both Sphygmo and the commercially available device). First, a nurse will fit a Sphygmo device cuff on one arm of the subject and the commercially available device cuff on the opposite arm. A trained research assistant will be continuously on hand to assist the nurse in the device setup and record the blood pressure measurements and any alarm indications made by each device. Blood pressure measurements by Sphygmo and the commercially available device will continue until monitoring is no longer clinically prescribed. In addition, blood pressure will be taken via clinical auscultatory measurement with a stethoscope and aneroid gauge at regular intervals. This third method will help us confirm the accuracy of the two devices. All clinical decisions will be made according to the commercially available device's measurements.

The key results of the study will be the ability of the Sphygmo device to identify blood pressure levels corresponding to mild and severe pre-eclampsia. Additionally, the investigators will document any user errors or device malfunction. These results will provide information on the performance and ease of use of the device and will also alert the research team of any necessary changes needed for the device.

Study Design

Study Type:
Interventional
Actual Enrollment :
11 participants
Allocation:
N/A
Intervention Model:
Single Group Assignment
Intervention Model Description:
Pregnant women will have their blood pressure measured by both the experimental device (Sphygmo ) and the gold-standard, commercial device (GE Dinamap Procare).Pregnant women will have their blood pressure measured by both the experimental device (Sphygmo ) and the gold-standard, commercial device (GE Dinamap Procare).
Masking:
None (Open Label)
Primary Purpose:
Device Feasibility
Official Title:
Pilot Clinical Assessment of the Diagnostic Capability, Usability, and Function of an Automatic Blood Pressure Monitor for Use in the Diagnosis and Management of Pre-eclampsia in a Low-resource Hospital
Actual Study Start Date :
Mar 1, 2015
Actual Primary Completion Date :
Oct 1, 2017
Actual Study Completion Date :
Oct 1, 2017

Arms and Interventions

Arm Intervention/Treatment
Experimental: Sphygmo

All subjects will have blood pressure measured by both the research device (Sphygmo) and the commercially available device. All clinical decisions will be made using measurements from the commercially available device

Device: Sphygmo
A team of engineers from Rice University has recently developed Sphygmo, an ambulatory, low-cost blood pressure monitor for use in the diagnosis and management of pre-eclampsia in low-resource hospitals

Outcome Measures

Primary Outcome Measures

  1. Accuracy of Blood Pressure Measurement by Sphygmo Relative to the Clinical Standard. [Measured during a single study visit, up to 24-72 hours.]

    Mean systolic and diastolic pressures measured by the Sphygmo device blood pressure measurement and the commercially available device. Measurements were taken multiple times over the course of 24-72 hours at intervals determined by the supervising clinician. Mean blood pressure for each participant was measured using each device and compared between the two devices (Sphygmo minus Standard). The reported values represent the mean systolic and diastolic blood pressures measured by Sphygmo vs Gold Standard device, averaged across all participants

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
Female
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Women who have been identified as at-risk for pre-eclampsia or have been diagnosed with pre-eclampsia during a visit to QECH.

  • Women who have been clinically identified to benefit from continuous blood pressure monitoring.

  • Women ages 18 or older.

Exclusion Criteria:
  • Pregnant women who have already developed eclampsia.

  • Women under age 18.

Contacts and Locations

Locations

Site City State Country Postal Code
1 Queen Elizabeth Central Hospital Blantyre Malawi

Sponsors and Collaborators

  • William Marsh Rice University
  • University of Malawi

Investigators

  • Principal Investigator: Rebecca R Richards-Kortum, PhD, William Marsh Rice University
  • Principal Investigator: Ronald Mataya, MD, University of Malawi

Study Documents (Full-Text)

More Information

Publications

Responsible Party:
Rebecca Richards-Kortum, Stanley C. Moore Professor of Bioengineering, William Marsh Rice University
ClinicalTrials.gov Identifier:
NCT02258256
Other Study ID Numbers:
  • 14-082F-C
  • (COMREC) P.04/14/1548
First Posted:
Oct 7, 2014
Last Update Posted:
Aug 10, 2021
Last Verified:
Aug 1, 2021
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

Participant Flow

Recruitment Details
Pre-assignment Detail
Arm/Group Title Preeclamptic Women
Arm/Group Description All subjects are pre-eclamptic women who will have their blood pressure measured by both the research device (Sphygmo) and the commercially available device. All clinical decisions will be made using measurements from the commercially available device Sphygmo: A team of engineers from Rice University has recently developed Sphygmo, an ambulatory, low-cost blood pressure monitor for use in the diagnosis and management of pre-eclampsia in low-resource hospitals
Period Title: Overall Study
STARTED 11
COMPLETED 11
NOT COMPLETED 0

Baseline Characteristics

Arm/Group Title Preeclamptic Women
Arm/Group Description All subjects are pre-eclamptic women who will have their blood pressure measured by both the research device (Sphygmo) and the commercially available device. All clinical decisions will be made using measurements from the commercially available device Sphygmo: A team of engineers from Rice University has recently developed Sphygmo, an ambulatory, low-cost blood pressure monitor for use in the diagnosis and management of pre-eclampsia in low-resource hospitals
Overall Participants 11
Age (years) [Median (Full Range) ]
Median (Full Range) [years]
28
Sex: Female, Male (Count of Participants)
Female
11
100%
Male
0
0%
Race (NIH/OMB) (Count of Participants)
American Indian or Alaska Native
0
0%
Asian
0
0%
Native Hawaiian or Other Pacific Islander
0
0%
Black or African American
11
100%
White
0
0%
More than one race
0
0%
Unknown or Not Reported
0
0%
Region of Enrollment (participants) [Number]
Malawi
11
100%

Outcome Measures

1. Primary Outcome
Title Accuracy of Blood Pressure Measurement by Sphygmo Relative to the Clinical Standard.
Description Mean systolic and diastolic pressures measured by the Sphygmo device blood pressure measurement and the commercially available device. Measurements were taken multiple times over the course of 24-72 hours at intervals determined by the supervising clinician. Mean blood pressure for each participant was measured using each device and compared between the two devices (Sphygmo minus Standard). The reported values represent the mean systolic and diastolic blood pressures measured by Sphygmo vs Gold Standard device, averaged across all participants
Time Frame Measured during a single study visit, up to 24-72 hours.

Outcome Measure Data

Analysis Population Description
[Not Specified]
Arm/Group Title Preeclamptic Women
Arm/Group Description All subjects are pre-eclamptic women who will have their blood pressure measured by both the research device (Sphygmo) and the commercially available device. All clinical decisions will be made using measurements from the commercially available device Sphygmo: A team of engineers from Rice University has recently developed Sphygmo, an ambulatory, low-cost blood pressure monitor for use in the diagnosis and management of pre-eclampsia in low-resource hospitals
Measure Participants 11
Systolic Mean BP - Sphygmo
125.3
(31.8)
Mean Diastolic BP - Sphygmo
85.2
(29.8)
Mean Systolic BP - GE Dinamap
129.8
(24.8)
Mean Diastolic BP - GE Dinamap
76.9
(17.0)

Adverse Events

Time Frame Adverse event data were collected over the length of the subject visit (24-72 hours).
Adverse Event Reporting Description
Arm/Group Title Preeclamptic Women
Arm/Group Description All subjects are pre-eclamptic women who will have their blood pressure measured by both the research device (Sphygmo) and the commercially available device. All clinical decisions will be made using measurements from the commercially available device Sphygmo: A team of engineers from Rice University has recently developed Sphygmo, an ambulatory, low-cost blood pressure monitor for use in the diagnosis and management of pre-eclampsia in low-resource hospitals
All Cause Mortality
Preeclamptic Women
Affected / at Risk (%) # Events
Total 0/11 (0%)
Serious Adverse Events
Preeclamptic Women
Affected / at Risk (%) # Events
Total 0/11 (0%)
Other (Not Including Serious) Adverse Events
Preeclamptic Women
Affected / at Risk (%) # Events
Total 0/11 (0%)

Limitations/Caveats

[Not Specified]

More Information

Certain Agreements

Principal Investigators are NOT employed by the organization sponsoring the study.

There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.

Results Point of Contact

Name/Title Dr. Rebecca Richards-Kortum
Organization Rice 360: Institute for Global Health
Phone 713-348-3823
Email rkortum@rice.edu
Responsible Party:
Rebecca Richards-Kortum, Stanley C. Moore Professor of Bioengineering, William Marsh Rice University
ClinicalTrials.gov Identifier:
NCT02258256
Other Study ID Numbers:
  • 14-082F-C
  • (COMREC) P.04/14/1548
First Posted:
Oct 7, 2014
Last Update Posted:
Aug 10, 2021
Last Verified:
Aug 1, 2021